Minerva Neurosciences, Inc

2.84 USD
+0.04 (+1.43%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Minerva Neurosciences, Inc stock is down -66.59% since 30 days ago. The next earnings date is May 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 9 February’s closed higher than January.

About Minerva Neurosciences, Inc

Minerva Neurosciences, Inc. focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for schizophrenia; MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for Parkinson's disease and other neurodegenerative disorders.